ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
ProKidney (NASDAQ: PROK) reported significant regulatory and clinical milestones in Q2 2025. The FDA confirmed eGFR slope as an acceptable surrogate endpoint for rilparencel's accelerated approval in type 2 diabetes and advanced CKD patients. The Phase 2 REGEN-007 study showed promising results with a 78% improvement in eGFR slope in Group 1 patients.
The company's Phase 3 PROACT 1 study has enrolled over 50% of required patients, with topline data expected in Q2 2027. ProKidney ended Q2 with $294.7 million in cash, supporting operations into mid-2027. Q2 financial results showed R&D expenses of $25.9 million (down from $29.4M in Q2 2024) and a net loss of $37.0 million.
ProKidney (NASDAQ: PROK) ha annunciato importanti traguardi normativi e clinici nel secondo trimestre 2025. La FDA ha confermato la pendenza dell'eGFR come endpoint surrogato accettabile per l'approvazione accelerata di rilparencel nei pazienti con diabete di tipo 2 e CKD avanzata. Lo studio di Fase 2 REGEN-007 ha mostrato risultati promettenti con un miglioramento del 78% della pendenza dell'eGFR nei pazienti del Gruppo 1.
Lo studio di Fase 3 PROACT 1 ha arruolato oltre il 50% dei pazienti richiesti, con i dati principali attesi nel secondo trimestre del 2027. ProKidney ha chiuso il Q2 con $294.7 million in cassa, a supporto delle operazioni fino a metà 2027. I risultati finanziari del Q2 hanno evidenziato spese di R&S per $25.9 million (in calo rispetto a $29.4M nel Q2 2024) e una perdita netta di $37.0 million.
ProKidney (NASDAQ: PROK) informó hitos regulatorios y clínicos relevantes en el segundo trimestre de 2025. La FDA confirmó la pendiente del eGFR como endpoint sustituto aceptable para la aprobación acelerada de rilparencel en pacientes con diabetes tipo 2 y ERC avanzada. El estudio de Fase 2 REGEN-007 mostró resultados prometedores con una mejora del 78% en la pendiente del eGFR en pacientes del Grupo 1.
El estudio de Fase 3 PROACT 1 ha enrolado más del 50% de los pacientes requeridos, con los datos principales previstos para el segundo trimestre de 2027. ProKidney cerró el Q2 con $294.7 million en efectivo, que financian las operaciones hasta mediados de 2027. Los resultados financieros del Q2 mostraron gastos en I+D de $25.9 million (frente a $29.4M en Q2 2024) y una pérdida neta de $37.0 million.
ProKidney (NASDAQ: PROK)는 2025년 2분기에 중요한 규제 및 임상 성과를 보고했습니다. FDA는 제2형 당뇨병 및 진행성 CKD 환자에 대한 rilparencel의 가속 승인에 대해 eGFR 기울기를 허용 가능한 대리 종결점(서러게이트 엔드포인트)으로 인정eGFR 기울기가 78% 개선되는 유망한 결과를 보였습니다.
3상 PROACT 1 연구는 필요한 환자의 50% 이상을 등록했으며, 주요 결과는 2027년 2분기에 발표될 예정입니다. ProKidney는 2분기 말 $294.7 million의 현금을 보유해 2027년 중반까지 운영을 지원할 수 있습니다. 2분기 재무 결과는 R&D 비용이 $25.9 million(2024년 2분기 $29.4M 대비 감소)이며 순손실은 $37.0 million입니다.
ProKidney (NASDAQ: PROK) a annoncé des étapes réglementaires et cliniques importantes au deuxième trimestre 2025. La FDA a confirmé la pente de l'eGFR comme critère substitut acceptable pour l'approbation accélérée de rilparencel chez les patients atteints de diabète de type 2 et d'une MRC avancée. L'étude de phase 2 REGEN-007 a montré des résultats prometteurs avec une amélioration de 78% de la pente de l'eGFR chez les patients du Groupe 1.
L'étude de phase 3 PROACT 1 a recruté plus de 50% des patients requis, les données principales étant attendues au T2 2027. ProKidney a clôturé le T2 avec $294.7 million de liquidités, couvrant les opérations jusqu'au milieu de 2027. Les résultats financiers du T2 montrent des dépenses R&D de $25.9 million (contre $29.4M au T2 2024) et une perte nette de $37.0 million.
ProKidney (NASDAQ: PROK) meldete im 2. Quartal 2025 bedeutende regulatorische und klinische Meilensteine. Die FDA bestätigte die eGFR-Steigung als akzeptablen Surrogatendpunkt für eine beschleunigte Zulassung von rilparencel bei Patienten mit Typ-2-Diabetes und fortgeschrittener CKD. Die Phase-2-Studie REGEN-007 zeigte bei Patienten der Gruppe 1 vielversprechende Ergebnisse mit einer 78%igen Verbesserung der eGFR-Steigung.
Die Phase-3-Studie PROACT 1 hat über 50% der benötigten Patienten eingeschlossen; die Topline-Daten werden für Q2 2027 erwartet. ProKidney beendete das 2. Quartal mit $294.7 million in bar, was die Geschäftstätigkeit bis Mitte 2027 absichert. Die Q2-Finanzergebnisse zeigten F&E-Aufwendungen von $25.9 million (gegenüber $29.4M im Q2 2024) und einen Nettoverlust von $37.0 million.
- FDA confirmation of eGFR slope as acceptable surrogate endpoint for accelerated approval pathway
- Phase 2 REGEN-007 showed 78% improvement in eGFR slope with statistical significance
- Strong cash position of $294.7M supporting operations into mid-2027
- Over 50% enrollment achieved in Phase 3 PROACT 1 study
- No rilparencel-related serious adverse events observed in clinical trials
- Net loss of $37.0M in Q2 2025
- Cash position decreased from $328.5M to $294.7M quarter-over-quarter
- Topline data for accelerated approval not expected until Q2 2027
Insights
ProKidney reports significant FDA alignment on accelerated approval pathway and positive Phase 2 data for rilparencel in diabetic CKD.
ProKidney has achieved two critical milestones that substantially de-risk their clinical development program for rilparencel. The FDA's confirmation that eGFR slope can serve as a surrogate endpoint for accelerated approval represents a major regulatory breakthrough. This pathway typically shortens the approval timeline by years compared to waiting for hard clinical outcomes.
The specific FDA agreement on an effect size of ≥1.5 mL/min/1.73m² per year improvement versus control provides clear efficacy targets. What's particularly promising is that their Phase 2 REGEN-007 data showed a 4.6 mL/min/1.73m² improvement, which exceeds this threshold by more than 3-fold.
The 78% reduction in kidney function decline observed in the Phase 2 study is remarkable. For context, most approved therapies for diabetic kidney disease typically slow progression by only 20-40%. If replicated in Phase 3, this would represent a paradigm-shifting treatment effect.
Enrollment progress is also encouraging, with over 50% of the required patients already recruited for the accelerated approval analysis. The
The favorable safety profile, showing no rilparencel-related serious adverse events, is critical for an invasive cell therapy. This safety data, combined with the efficacy signal and regulatory clarity, positions ProKidney well for their pivotal Phase 3 program and potential commercialization of what could be the first disease-modifying cellular therapy for diabetic kidney disease.
- FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type 2 diabetes and advanced CKD; FDA also confirmed that the ongoing Phase 3 PROACT 1 study may be used to support both accelerated and confirmatory approval of rilparencel
- More than half of the patients required for the accelerated approval analysis using eGFR slope have been enrolled in the Phase 3 PROACT 1 study; topline data anticipated in Q2 2027
- On July 8, 2025, ProKidney reported positive topline results from the Phase 2 REGEN-007 study; eGFR slope in Group 1 (n=24) improved by
78% after treatment with rilparencel - Full results from REGEN-007 will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trial
- Ended the second quarter with
$295 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027
WINSTON-SALEM, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapeutics company focused on chronic kidney disease (CKD), today reported financial results for the second quarter ended June 30, 2025, and provided regulatory and clinical updates.
“We’ve made tremendous progress in 2025, and July was a pivotal month for ProKidney with the release of positive topline data from our Phase 2 REGEN-007 study and alignment with the FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpoint,” said Bruce Culleton, M.D., CEO of ProKidney. “We are now focused on maintaining enrollment momentum in the Phase 3 PROACT 1 study and preparing for a late-breaking submission of Phase 2 REGEN-007 data at ASN Kidney Week in November. Each step brings us closer to our goal of delivering a novel treatment option to patients with diabetes and advanced CKD, a population where there remains high unmet clinical need.”
FDA Alignment Achieved for the Rilparencel Accelerated Approval Pathway
In a July 2025 Type B meeting, the U.S. Food and Drug Administration (FDA) confirmed that the slope of estimated glomerular filtration rate (eGFR) in patients from the ongoing Phase 3 PROACT 1 study can serve as the surrogate endpoint and primary basis for a Biologics License Application (BLA) submission of rilparencel under the accelerated approval pathway. The FDA agreed that a rilparencel effect size (versus sham controls) of at least 1.5 mL/min/1.73m2 per year improvement would be an acceptable demonstration of efficacy in the setting of patients receiving appropriate standard of care therapies.
ProKidney anticipates topline data readout of eGFR slope as the surrogate endpoint to support an application for accelerated approval in Q2 2027. To date, more than half of the approximately 350 patients required for the accelerated approval analysis have been enrolled in the ongoing Phase 3 PROACT 1 study. The FDA also confirmed that PROACT 1 may serve as the confirmatory study to support full approval of rilparencel based on the primary time-to-event composite endpoint specified in the protocol. Formal meeting minutes from the FDA following the Type B meeting held in July 2025 confirm alignment with ProKidney. ProKidney will continue to maintain its ongoing dialogue with the FDA under rilparencel’s regenerative medicine advanced therapy (RMAT) designation.
Phase 2 REGEN-007 Positive Topline Results
On July 8, 2025, ProKidney announced statistically and clinically significant topline results from the Phase 2 REGEN-007 study. Of note, in Group 1 (n=24), which replicated the rilparencel dosing schedule of the ongoing Phase 3 PROACT 1 study, kidney function stabilized. The annual decline in eGFR slope improved by
No rilparencel-related serious adverse events were observed across all patients in the study who received at least one rilparencel injection (n=49). The safety profile was consistent with previously reported study results and comparable to a kidney biopsy.
Full results from REGEN-007 will be submitted to the American Society of Nephrology (ASN) as a late-breaking clinical trial at Kidney Week 2025.
________________________
1 Difference in values is due to rounding.
Second Quarter 2025 Financial Highlights
Effective July 1, 2025, ProKidney completed a domestication process through which the Company and certain subsidiaries changed their jurisdiction of incorporation from the Cayman Islands and other jurisdictions to the State of Delaware.
Liquidity: Cash, cash equivalents and marketable securities as of June 30, 2025, totaled
R&D Expenses: Research and development expenses were
G&A Expenses: General and administrative expenses were
Net Loss Before Noncontrolling Interest: Net loss before noncontrolling interest was
Shares outstanding: Class A and Class B common stock outstanding as of June 30, 2025 totaled 292,707,888.
About Chronic Kidney Disease
CKD is a progressive condition characterized by the gradual decline of kidney function, which can ultimately lead to end-stage kidney disease (ESKD) requiring dialysis or transplantation. An estimated 37 million adults in the U.S. have CKD, though many remain undiagnosed in the early stages. Diabetes is the leading cause of CKD, and individuals with both conditions face significantly elevated risks of cardiovascular events, hospitalization, and mortality. ProKidney is developing rilparencel for patients with Stage 3b/4 CKD and diabetes, a population that includes 1 to 2 million people in the U.S. While current treatment options aim to slow disease progression, there remains a substantial unmet need for therapies that can stabilize kidney function and delay or prevent the need for dialysis in patients with advanced CKD.
About the Phase 2 REGEN-007 Clinical Trial
REGEN-007 was a multi-center Phase 2 open-label 1:1 randomized two-armed trial in patients with diabetes and CKD who have an eGFR of 20-50 mL/min/1.73m². At randomization, patients were assigned to one of two treatment groups using different dosing regimens. Group 1 replicated the dosing schedule of the ongoing Phase 3 PROACT 1 study in which patients received two scheduled rilparencel injections (one in each kidney), approximately three months apart. Group 2 tested an exploratory dosing regimen to investigate whether disease progression triggers, rather than a time-based trigger, could optimize multiple administrations of rilparencel. In Group 2, patients received a single rilparencel injection in one kidney and a second injection in the contralateral kidney only if triggered by a sustained eGFR decline from baseline of ≥
About the Phase 3 REGEN-006 (PROACT 1) Clinical Trial
REGEN-006 is an ongoing Phase 3, randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with advanced CKD and type 2 diabetes. The study protocol was amended in 1H 2024 to focus on a subset of patients with Stage 4 CKD (eGFR 20-30 mL/min/1.73m2) and late Stage 3b CKD (eGFR 30-35 mL/min/1.73m2) with accompanying albuminuria (UACR less than 5,000 mg/g for patients with eGFR 20-30 mL/min/1.73m2 and 300-5,000 mg/g for patients with eGFR 30-35 mL/min/1.73m2). The total planned enrollment is approximately 685 subjects. Subjects are randomized (1:1) to the treatment group and the sham control group prior to kidney biopsy or a sham biopsy procedure, respectively. The primary objective is to assess the efficacy of up to two rilparencel injections (one in each kidney) using a minimally invasive percutaneous approach. The surrogate endpoint for accelerated approval is eGFR slope, and the primary composite endpoint is the time from first injection to the earliest of: at least
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy with RMAT designation that is being evaluated for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. For more information, please visit www.prokidney.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s beliefs that its Phase 3 REGEN-006 (PROACT 1) trial could be sufficient to support a potential BLA submission and full regulatory approval, eGFR slope can be used as a surrogate endpoint on an accelerated approval pathway for rilparencel, expectations with respect to financial results and expected cash runway, including the Company’s expectation that current cash will support operating plans into mid-2027, future performance, development and commercialization of products, if approved, the potential benefits and impact of the Company’s products, if approved, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s products, if approved, the advancement of the Company’s development programs into and through the clinic and the expected timing for reporting data, the making of regulatory filings or achieving other milestones related to the Company’s product candidates, and the advancement and funding of the Company’s developmental programs, generally. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: disruptions to our business or that may otherwise materially harm our results of operations or financial condition as a result of our recent domestication to the United States; the inability to maintain the listing of the Company’s Class A common stock on Nasdaq; the inability of the Company’s Class A common stock to remain included in various indices and the potential negative impact on the trading price of the Class A common stock if excluded from such indices; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the risk that results of the Company’s clinical trials may not support approval; the risk that the FDA could require additional studies before approving the Company’s drug candidates; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company’s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the fact that interim results from our clinical programs may not be indicative of future results; the impact of geo-political conflict on the Company’s business; and other risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Investor Contacts:
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
| ProKidney Corp. and Subsidiaries Consolidated Balance Sheets (in thousands, except for share data)2 | ||||||||
| June 30, 2025 | December 31, 2024 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Cash and cash equivalents | $ | 84,940 | $ | 99,120 | ||||
| Marketable securities | 209,788 | 259,172 | ||||||
| Interest receivable | 1,775 | 2,447 | ||||||
| Prepaid assets | 2,300 | 4,192 | ||||||
| Prepaid clinical | 5,723 | 11,505 | ||||||
| Assets held for sale | 19,368 | 19,368 | ||||||
| Other current assets | 546 | 80 | ||||||
| Total current assets | 324,440 | 395,884 | ||||||
| Fixed assets, net | 43,525 | 42,222 | ||||||
| Right of use assets, net | 4,168 | 2,967 | ||||||
| Total assets | $ | 372,133 | $ | 441,073 | ||||
| Liabilities and Stockholders' Deficit | ||||||||
| Accounts payable | $ | 2,443 | $ | 3,633 | ||||
| Lease liabilities | 903 | 765 | ||||||
| Accrued expenses and other | 24,916 | 31,137 | ||||||
| Income taxes payable | – | 682 | ||||||
| Total current liabilities | 28,262 | 36,217 | ||||||
| Income tax payable, net of current portion | 903 | 748 | ||||||
| Lease liabilities, net of current portion | 3,515 | 2,471 | ||||||
| Total liabilities | 32,680 | 39,436 | ||||||
| Commitments and contingencies | ||||||||
| Redeemable noncontrolling interest | 1,341,953 | 1,396,591 | ||||||
| Stockholders’ deficit | ||||||||
| Class A common stock, authorized; 133,418,957 and 128,054,417 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 13 | 13 | ||||||
| Class B common stock, authorized; 159,288,931 and 163,693,707 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 16 | 16 | ||||||
| Additional paid-in capital | 231,576 | 205,736 | ||||||
| Accumulated other comprehensive gain | 30 | 130 | ||||||
| Accumulated deficit | (1,234,135 | ) | (1,200,849 | ) | ||||
| Total stockholders' deficit | (1,002,500 | ) | (994,954 | ) | ||||
| Total liabilities and stockholders' deficit | $ | 372,133 | $ | 441,073 | ||||
________________________
2 For presentation purposes, unless otherwise noted, “ordinary shares” before the domestication and “common stock” subsequent to the domestication are referred to herein as common stock
| ProKidney Corp. and Subsidiaries Consolidated Statements of Operations - Unaudited (in thousands, except for share and per share data)3 | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ | 221 | $ | – | $ | 451 | $ | – | ||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 25,882 | 29,404 | 53,145 | 56,637 | ||||||||||||
| General and administrative | 14,048 | 13,652 | 28,403 | 26,495 | ||||||||||||
| Total operating expenses | 39,930 | 43,056 | 81,548 | 83,132 | ||||||||||||
| Operating loss | (39,709 | ) | (43,056 | ) | (81,097 | ) | (83,132 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 3,593 | 4,537 | 7,620 | 9,380 | ||||||||||||
| Interest expense | (1 | ) | (3 | ) | (1 | ) | (5 | ) | ||||||||
| Net loss before income taxes | (36,117 | ) | (38,522 | ) | (73,478 | ) | (73,757 | ) | ||||||||
| Income tax expense (benefit) | 848 | (56 | ) | 1,439 | 42 | |||||||||||
| Net loss before noncontrolling interest | (36,965 | ) | (38,466 | ) | (74,917 | ) | (73,799 | ) | ||||||||
| Net loss attributable to noncontrolling interest | (20,413 | ) | (25,960 | ) | (41,631 | ) | (51,801 | ) | ||||||||
| Net loss available to Class A common stockholders | $ | (16,552 | ) | $ | (12,506 | ) | $ | (33,286 | ) | $ | (21,998 | ) | ||||
| Weighted average shares of Class A common stock outstanding: | ||||||||||||||||
| Basic and diluted | 130,730,840 | 75,908,017 | 129,858,450 | 68,429,869 | ||||||||||||
| Net loss per share attributable to Class A common stock: | ||||||||||||||||
| Basic and diluted | $ | (0.13 | ) | $ | (0.16 | ) | $ | (0.26 | ) | $ | (0.32 | ) | ||||
________________________
3 For presentation purposes, unless otherwise noted, “ordinary shares” before the domestication and “common stock” subsequent to the domestication are referred to herein as common stock.
| ProKidney Corp. and Subsidiaries Consolidated Statements of Cash Flows - Unaudited (in thousands)4 | ||||||||
| Six Months Ended June 30, | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss before noncontrolling interest | $ | (74,917 | ) | $ | (73,799 | ) | ||
| Adjustments to reconcile net loss before noncontrolling interest to net cash flows used in operating activities: | ||||||||
| Depreciation and amortization | 3,065 | 2,372 | ||||||
| Equity-based compensation | 12,957 | 15,489 | ||||||
| Gain on marketable securities, net | (1,942 | ) | (3,802 | ) | ||||
| Loss on lease disposition | 143 | – | ||||||
| Loss on disposal of equipment | 464 | 131 | ||||||
| Changes in operating assets and liabilities | ||||||||
| Interest receivable | 672 | (1,373 | ) | |||||
| Prepaid and other assets | 7,202 | (6,162 | ) | |||||
| Accounts payable and accrued expenses | (8,126 | ) | (5,838 | ) | ||||
| Income taxes payable | (526 | ) | 43 | |||||
| Net cash flows used in operating activities | (61,008 | ) | (72,939 | ) | ||||
| Cash flows from investing activities | ||||||||
| Purchases of marketable securities | (98,138 | ) | (82,880 | ) | ||||
| Sales and maturities of marketable securities | 149,239 | 171,445 | ||||||
| Purchase of equipment and facility expansion | (4,247 | ) | (1,596 | ) | ||||
| Net cash flows provided by investing activities | 46,854 | 86,969 | ||||||
| Cash flows from financing activities | ||||||||
| Proceeds from sales of Class A common stock, net of offering costs | – | 139,855 | ||||||
| Payments on finance leases | (26 | ) | (26 | ) | ||||
| Net cash flows (used in) provided by financing activities | (26 | ) | 139,829 | |||||
| Net change in cash and cash equivalents | (14,180 | ) | 153,859 | |||||
| Cash, beginning of period | 99,120 | 60,649 | ||||||
| Cash, end of period | $ | 84,940 | $ | 214,508 | ||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Right of use assets obtained in exchange for lease obligations | $ | 2,005 | $ | 2,621 | ||||
| Exchange of Class B common stock | $ | 5,253 | $ | 14,902 | ||||
| Impact of equity transactions and compensation on redeemable noncontrolling interest | $ | 7,756 | $ | 16,708 | ||||
| Equipment and facility expansion included in accounts payable and accrued expenses | $ | 395 | $ | 780 | ||||
________________________
4 For presentation purposes, unless otherwise noted, “ordinary shares” before the domestication and “common stock” subsequent to the domestication are referred to herein as common stock.
FAQ
What did the FDA confirm about ProKidney's rilparencel approval pathway in July 2025?
What were the key results from ProKidney's Phase 2 REGEN-007 study?
When does PROK expect topline data for rilparencel's accelerated approval?
What is ProKidney's current cash runway?
How many patients are enrolled in ProKidney's Phase 3 PROACT 1 study?
